Basit öğe kaydını göster

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

dc.contributor.authorKahraman, Seda
dc.contributor.authorErul, Enes
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorGümüşay, Özge
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorDemirel, Burçin Çakan
dc.contributor.authorAcar, Ömer
dc.contributor.authorAksoy, Sercan
dc.contributor.authorBaytemur, Nazife Köse
dc.contributor.authorŞahin, Elif
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorBaşaran, Gül
dc.contributor.authorPaydaş, Semra
dc.contributor.authorYaren, Arzu
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorErdoğan, Atike Pınar
dc.contributor.authorDemirci, Umut
dc.contributor.authorYaşar, Alper
dc.contributor.authorBayoğlu, İbrahim Vedat
dc.contributor.authorHızal, Mutlu
dc.contributor.authorGülbağcı, Mutlu
dc.contributor.authorPaksoy, Nail
dc.contributor.authorDavarcı, Sena Ece
dc.contributor.authorYılmaz, Funda
dc.contributor.authorDoğan, Özlem
dc.contributor.authorOrhan, Sibel Oyucu
dc.contributor.authorKayıkcıoğlu, Erkan
dc.contributor.authorAytaç, Ali
dc.contributor.authorKeskinkılıç, Merve
dc.contributor.authorMoçan, Eda Eylemer
dc.contributor.authorÜnal, Ölçün Ümit
dc.contributor.authorAydın,Esra
dc.contributor.authorYücel, Hakan
dc.contributor.authorIşık, Deniz
dc.contributor.authorEren, Önder
dc.contributor.authorUluç, Başak Oyan
dc.contributor.authorÖzçelik, Melike
dc.contributor.authorHacıbekiroğlu, İlhan
dc.contributor.authorAydıner, Adnan
dc.contributor.authorDemir, Hacer
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorÇılbır, Ebru
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorÇetin, Bülent
dc.contributor.authorOktay, Esin
dc.contributor.authorErol, Cihan
dc.contributor.authorOkutur, Sadi Kerem
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorAlkan, Ali
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorAksoy, Asude
dc.contributor.authorKarakaş, Yusuf
dc.contributor.authorÖzkanlı, Gülhan
dc.contributor.authorDuman, Berna Bozkurt
dc.contributor.authorAydın, Dinçer
dc.contributor.authorDulgar, Özgecan
dc.contributor.authorEr, Muhammed Muhiddin
dc.contributor.authorTeker, Fatih
dc.contributor.authorYavuzsen, Tuğba
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorİnal, Ali
dc.contributor.authorİriağaç, Yakup
dc.contributor.authorKalkan, Nurhan Önal
dc.contributor.authorKeser, Murat
dc.contributor.authorSakalar, Teoman
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorKut, Engin
dc.contributor.authorBilgin, Burak
dc.contributor.authorKaraoğlanoğlu, Müge
dc.contributor.authorSunar, Veli
dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorTurhal, Nazım Serdar
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorYalçın, Bülent
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.date.accessioned2023-09-11T05:51:18Z
dc.date.available2023-09-11T05:51:18Z
dc.date.issued2023en_US
dc.identifier.citationKahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., Acar, O., Aksoy, S., Baytemur, N. K., Sahin, E., Cabuk, D., Basaran, G., Paydas, S., Yaren, A., Guven, D. C., Erdogan, A. P., Demirci, U., Yasar, A., Bayoglu, İ. V., Hizal, M., … Nahit Sendur, M. A. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future oncology (London, England), 19(10), 727–736. https://doi.org/10.2217/fon-2022-1287en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.urihttps://doi.org/10.2217/fon-2022-1287
dc.identifier.urihttps://hdl.handle.net/11436/8282
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.en_US
dc.language.isoengen_US
dc.publisherFuture Medicine Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCDK 4en_US
dc.subject6 inhibitorsen_US
dc.subjectHER2-negative metastatic breast canceren_US
dc.subjectHR-positiveen_US
dc.subjectLetrozoleen_US
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast canceren_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorAydın, Esra
dc.identifier.doi10.2217/fon-2022-1287en_US
dc.identifier.volume19en_US
dc.identifier.issue10en_US
dc.identifier.startpage727en_US
dc.identifier.endpage736en_US
dc.relation.journalFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster